Holding a webinar on alpha emitting radiopharmaceuticals by Pars Isotope
The webinar entitled “Latest Scientific Advances in Alpha Emitting Radiopharmaceuticals” was held by Pars Isotope for the first time in Iran.
Pars Isotope Company, as the sole custodian of the production and supply of radiopharmaceuticals and radiopharmaceutical kits in Iran, organized for the first time in Iran a webinar on alpha emitting radiopharmaceuticals, entitled “Latest Scientific Advances in Alpha Emitting Radiopharmaceuticals”. This webinar was held for 3 hours on 17 September 2021 with the presence of 3 domestic speakers and 3 foreign speakers from Netherlands, Italy and India. In addition, more than 150 domestic and foreign interested people participated in this event.
The scientific secretary of this webinar was Professor Majid Asadi, a nuclear medicine specialist, Head of the Persian Gulf Nuclear Medicine Research Center and a faculty member of Bushehr University of Medical Sciences. The main focus of this webinar was on recent scientific advances in the field of alpha emitting radioisotopes, the characteristics of alpha emitting radiopharmaceuticals, how they are produced and their therapeutic applications. The participants of this webinar included a wide range of nuclear medicine specialists, staff of nuclear medicine centers, oncologists, nuclear pharmacists, professors and students in this field and other interested people from inside and outside Iran. By the end, the applicant participants received a certificate of participation in the webinar from Pars Isotope Company.
Radiopharmaceutical therapy with alpha particle emitters is an emerging and promising strategy in the treatment of cancer that is fundamentally different from other common treatments. Due to their short range and high linear energy transfer, alpha emitting radioisotopes show great destructive effects on the cells and can be considered as a good treatment for small tumors and metastases without damaging the surrounding healthy tissues. Researchers have recently begun to use alpha emitting radionuclides, and this emerging technology will soon replace beta emitting radionuclides for therapeutic purposes.
Pars Isotope, as the sole custodian of the production and supply of radiopharmaceuticals and radiopharmaceutical kits in Iran, considers itself in line with the latest science in the world. Therefore, holding such scientific events as well as informing about them is one of its main tasks and goals.